We have recently demonstrated that loss of heterozygosity (LOH) at 7q31 is frequent in many kinds of human primary tumors and that introducing a single human chromosome (hchr) 7 into a murine squamous cell carcinoma (SCC)-derived cell line suppresses the malignant phenotype. To investigate whether the putative tumor suppressor gene on hchr 7 is conserved in mice, we studied LOH on mouse chromosome (mchr) 6 in chemically induced SCCs in (C57BL6DBA2) F1 (B6D2F1) females. LOH analysis was performed by polymerase chain reaction ampli®cation of 17 (CA) n microsatellite repeats in mchr 6 A1-C3. As expected, all the B6D2F1-derived tumors were informative for all the locus assayed. The highest percentage of LOH in the hchr 7q-homologous segment was found at D6Mit50 (60.0%) and the other markers in this segment had LOH incidences normally distributed around the peak. The high incidence of LOH in the tumors studied suggests that a tumor suppressor gene relevant to the development of epithelial cancers is present on mchr 6 A2. As this segment is homologous with hchr 7q31, these data suggest that the putative tumor suppressor gene is conserved in the two species and explains the suppression of tumorigenicity when a single hchr 7 is introduced to a murine SCC cell line.
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Introduction
We recently reported that LOH at 7q31.1-31.2 is a very common event in human primary breast, prostate, colon, ovarian and squamous cell carcinomas (Zenklusen et al., ,c, 1995a rev. Zenklusen and Conti, 1996) . These data agree with cytogenetic reports indicating that deletions of human chromosome (hchr) 7 are common in many dierent types of tumors, including ovarian cancer, gastric carcinomas, and malignant myeloid tumors (Kere et al., 1989; Atkin and Baker, 1991; Osella et al., 1992; Abrahamson et al., 1993; Atkin and Baker, 1993; Kibbelaar et al., 1993) .
Even though most of the tumor suppressor genes (TSGs) have been discovered and cloned in humans, all of them have been shown to be of importance in animal models of cancer. In fact, all the TSGs have been mapped to mchrs that are homologous with the hchrs that bear the corresponding human loci and have been shown to code for proteins highly conserved across species (Weinberg, 1991; Lehmam et al., 1991; Conti et al., 1992; Bowden et al., 1994) .
The mouse skin carcinogenesis model has been successfully used by a number of groups as an experimental model for neoplasia (DiGiovanni, 1991; Boyd and Barrett, 1991; Conti, 1994; Yuspa et al., 1994) . Because it is a well-characterized system with a de®ned sequence of events leading to the production of SCCs, it has been used by various groups to study the genetic events that occur during carcinogenesis. Using this model, Kemp et al. (1993) found allelic imbalance in chemically induced mouse skin tumors by using markers that mapped to a mchr region homologous to hchr 7q31. Moreover, our results using microcell fusion transfer of hchr 7 into a SENCAR-derived SCC cell line indicated that hchr 7 can delay the onset of tumors by two-to threefold and in some cases even completely repress the tumorigenicity of the SCC cell line used. In situ hybridization revealed that the clones that reverted to the malignant phenotype had lost the inserted chromosome (Zenklusen et al., 1994a) .
Taken together, this evidence suggests that there is a putative TSG in the A2 band of mchr 6, which is homologous to hchr 7q31. To investigate this possibility, we used an extensive set of highly polymorphic markers in the mchr 6 A1-C3 (mchr 6A1-C3) segment to assess LOH in tumors induced by chemical carcinogenesis.
Results
Seventeen (CA) n microsatellite repeats (Copeland et al., 1993; Dietrich et al., 1994 ; Whitehead Institute/MIT Center for Genome Research, 1994) ampli®ed by PCR were used to screen eight short term cultured SCCs and 10 microdissected SCCs for LOH at 6 A1-C3 (six of these cases were common with the STC SCCs). In each case, both STCs and microdissected paran sections gave the same results. The cases that had both STCs and paran sections were counted as one case for the LOH analysis, giving a total of 12 cases. Figure 1 shows representative photographs of (CA) n microsatellite ampli®cations. The results obtained are summarized in Table 1 .
Our results indicated that partial loss of that segment of mchr 6 is a common event in two-stage carcinogenesis in SCCs. In all tumors but one, LOH occurred in at least one 6 A1-C3 locus. As can be seen in Figure 2 , LOH occurred most frequently (60.0%) in D6Mit50, which is in the region homologous to hchr 7q. Furthermore, the segment delimited by D6Mit179 and D6Mit50 had an average percentage LOH of 55.0%. The percentage of LOH in the segment of mchr 6 that is homologous with hchr was found to have a Gaussian distribution (Kolmogorov-Smirnov test; Zar, 1991) , as would be expected from the stochastic inactivation of a TSG. D6Mit29 in mchr 6 band C3 was also found to have a high LOH incidence (55.6%). We found no evidence of genetic instability (microsatellites or replication errors), as detected in other models by other groups (Canzian et al., 1994; Mao et al., 1994; Loeb, 1994) but consistent with the data of Sasaki et al. (1995) that showed no genetic instability in the two stage skin carcinogenesis model. Figure 3 displays a schematic representation of the deleted regions of mchr 6 in seven cases studied. In these cases, large deletions can be predicted by the molecular techniques used. The probability that three or more allelic losses occurred independently in the chromosomal region is very small, so the occurrence of such series of LOH of contiguous markers is more likely due to mitotic recombination or deletion of an entire segment that to separate small deletions. In some of our samples, the retention of the dierent parental alleles made a mosaic pattern: in dierent regions of the chromosome a dierent parental allele was preferentially retained. It is notable that the hchr 7q-homologous segment seemed to retain mostly the DBA/2 allele (®ve of seven LOH cases), while in the C3 locus the C57/BL allele was retained in all the cases with LOH.
Two of the cases studied (#9651 and 9768) showed doubled intensity in the C57/BL allele with respect to the DBA/2 band when measured by densitometry in all the markers assayed that showed no LOH. This indicates that those cases had a trisomy of mchr 6 with a ratio of two C57/B1 to one DBA/2 chromosome. Trisomy of this chromosome had been previously reported in the mouse skin carcinogenesis model by our laboratory (Aldaz et al., 1989) . However, in markers close to the areas of high LOH frequency, only the C57/BL allele band was observed, while the DBA/2 allele had disappeared. In order to determine the number of C57/BL allele present in these cases, multiplex PCR ampli®cation was performed with these markers and a neutral marker in the C1 band (D6Mit19). The intensity relation between the C57/ BL bands in the aected markers and the control marker showed that the LOH markers had three copies of the C57/BL allele, suggesting that a recombination event produced the LOH by replacing the DBA/2 allele with a C57/BL (Figure 4 ). 
Discussion
We assayed for LOH on mchr 6 in two-stage chemically induced carcinomas of B6D2F1 mice. We selected the (CA) n microsatellite repeats so that all the mice used in this study were informative for them by using only markers whose allelic size for the two parental strains diered in more than 4 bp. High frequency of LOH was found at D6Mit50 (60.0%) and D6Mit29 (55.6%). The ®rst marker maps to mchr 6 A2 which is homologous to hchr 7q31 (homology deducted by comparison of cytogenetic distance of anonymous marker and the met gene located in 7q31); the second marker maps to mchr 6 C3, a segment of unknown human homology. The high frequency of LOH at mchr 6A2 in B6D2F1 mice suggests that a TSG relevant to the development of SCC is located within this segment. This new LOH evidence in a murine experimental system supports a possible explanation for the repression of tumorigenicity observed previously in our lab (Zenklusen et al., 1994a) . Since the inactivation of this putative TSG on mchr 6 appears to be a common event in chemically induced SCC in mice, and the cell line we used for our microcell-mediated transfer experiments was derived from this type of SCCs, we hypothesize that the repression occurred because of the restoration of TSG activity by the homologous human gene present on the introduced hchr 7. Repression of tumorigenicity of a murine-derived SCC cell line by a protein encoded by a human chromosome suggests that this putative TSG is highly conserved between humans and mice.
We cannot speculate on the relevance of the other region that presented a LOH score higher than 50% in the tumors (D6Mit29) due to our lack of information on this segment, however this region should be studied carefully to determine if they contain any other putative TSGs.
The surprising pattern of deletions shown in Figure  3 seem to indicate that in dierent mchr 6 fragments one parental allele is preferentially retained creating a mosaic-like pattern. This pattern may be due to a series of microdeletions in one parental mchr or the other; or to mitotic recombination. Only these two explanations are consistent with the mosaic pattern we found, because the total loss or large deletions of one parental allele would result in LOH with retention of one allele and total absence of the other.
It has been postulated that inactivation of a TSG may occur by mitotic recombination with a defective chromatid on which the TSG is inactivated by deletion or point mutations (James et al., 1989; Mori et al., 1989) . Previous results from our laboratory (Bianchi et al., 1991) also showed that mitotic recombination is the (Aldaz et al., 1986) indicate the absence of structural chromosomal abnormalities. However, we have demonstrated that trisomization of both mchr 6 and 7 is a very frequent event in this model and that it follows a strict sequence (Aldaz et al., 1989) . Which mechanism could possibly explain the concurrence of trisomy and allelic loss? Once a chromosome bearing a mutated TSG is duplicated (by nondisjunction) producing a trisomy with two defective copies of the gene, complete inactivation of the TSG (as well as allelic loss) can be achieved through loss of the non-duplicated chromosome or mitotic recombination with the defective chromatid. We present data in this report showing that the trisomic tumors retain heterozygosity in most of the chromosome, but that heterozygosity is lost in some areas and three copies of same allele can be found in those segments. Our data thus suggests that LOH is produced from a trisomic chromosome by mitotic recombination of the segment containing the target TSGs with the homologous region in the other parental chromosome. This mechanism is only one of a series of possible ways to achieve allelic loss and does not seem to be the only one at work in our model since we found only two cases in which we could establish this pattern.
No reference to this mosaicism can be found in other LOH reports in murine carcinogenesis (Kemp et al., 1993; Davis et al., 1994; Hegi et al., 1994; Miyasaka et al., 1995; Ohsumi et al., 1995) indicating that this pattern may be a particularity of the twostage carcinogenesis model, probably related to the use of phorbol ester promoters. In this respect, it has been demonstrated, using in vitro systems, that 12-otetradecanoylphorbol-13-acetate (TPA) can induce sister chromatid exchanges as well as other chromosomal aberrations (Shiraishi, 1985; Emerit et al, 1989) . However, using the same protocol we employed, Kemp et al. (1993) report no such mosaicism in a genomewide allelotyping using only two or three markers per chromosome. This technical approach would not allow the detection of mosaicism due to the scarcity of markers employed. In view of this, we cannot ascertain if mitotic recombination is a common mechanism for TSG inactivation in general, or if it is a particularity of the two-stage carcinogenesis protocol. The mosaic pattern we found on mchr 6 in the cases presented in this study seems to suggest not only that mitotic recombination is the mechanism by which LOH occurred in this carcinogenesis protocol but that recombination may happen at a high frequency, leading to LOH greater than 50% at several loci on a single mchr. Further research needs to be done to con®rm the extent of this mechanism of inactivation in other systems such as a through screening for LOH on SCCs produced by an alternative protocol.
Materials and methods

Animals
Twelve B6D2F1 females from the National Cancer Institute (Frederick, MD) were used in these experiments. They were housed in groups of four in plastic cages, with unlimited water and food. All the animals were 4 ± 6 weeks old at the beginning of the treatment. SCCs were induced in the dorsal skin of each animal by treatment with a single dose of 100 nmol of 7,12-dimethylbenz[a]anthracence and repetitive applications of 5 mg of 12-o-tetradecanoylphorbol-13-acetate twice weekly. Tumors were collected after 35 ± 50 weeks of promotion. All tumors were ®xed in formalin and embedded in paran while only eight of them yielded enough material to establish short-term cultures (STC) to obtain stroma-free cultures. In the cases were both types of samples were available, no signi®cant dierence were found in the LOH obtained with DNA from microdissected paran sections or STC. The cases that had both STCs and paran sections were counted as one case for the LOH analysis, giving a total of 12 cases.
Short-term cultures
Samples were enzymatically dispersed into single cell suspensions by treatment with collagenase at 378C for 40 ± 50 min as described previously (Aldaz et al., 1986) , without the addition of demecolsine. The dispersed cells were centrifuged and resuspended in low-calcium (50 mM CaCl 2 ) Eagle's modi®ed essential medium essentially as previously described (Miller et al., 1987) but were supplemented with 1% fetal bovine serum and plated at 5610 5 ± 1610 6 viable cells per 25 cm 2¯a sk. The cultures were washed to eliminate unattached cells after 24 h, and harvested after 48 ± 72 h. The cells obtained were used for high-molecular-weight DNA extraction using a standard proteinase K-phenol-chloroform protocol (Ausubel et al., 1992) .
DNA extraction from paran sections
Samples were ®xed in normal buered formalin and paran-embedded until high-molecular-weight DNA was extracted from them. Eight-micrometer-thick tissue sections were cut from the paran-embedded blocks and placed on glass slides. Unstained sections were microdissected to separate normal and non-neoplastic tissue from the tumor. As reference, consecutive serial sections were stained with hematoxylin and eosin. High-molecularweight DNA was extracted from both lymph node and tumor sections by standard proteinase K digestion followed by chelex extraction (Ausubel et al., 1992) .
(CA) n microsatellite repeat ampli®cation analysis Seventeen (CA) n microsatellite repeats on mchr 6 (Copeland et al., 1993; Dietrich et al., 1994 ; Whitehead Institute/ MIT Center for Genome Research, 1994) were ampli®ed in a Thermocycler 9600 (Perkin-Elmer Cetus, Norwalk, CT). The 25 ml reaction mixtures contained 2.5 ml of 106 standard polymerase chain reaction (PCR) buer (PerkinElmer Cetus), 100 ng of DNA, 1 unit of Taq polymerase, 400 pM each primer and 200 mM each dNTP. Hot start was performed by using a Taq polymerase-speci®c antibody that inactivates the enzyme and is released during the ®rst denaturation cycle (Taq Start; Clontech, CA). The DNA was ampli®ed with 27 cycles of 20 s of denaturation at 948C, 30 s of annealing at 508C and 15 s of extension at 728C. The number of cycles used was in the linear part of the ampli®cation process, i.e., before production saturation, permitting us to assume that equal optical density of both alleles was to be expected if no LOH had occurred.
The PCR products were separated in a 3.5% MetaPhor agarose (FMC Bioproducts, Rockland, ME) gel by electrophoresis at 5.5 V/cm 2 for 3 h in TBE buer (89 mM Trisborate, 89 mM boric acid and 2 mM EDTA, pH 7.5) with 0.5 mg/ml ethidium bromide in TBE and a standard loading buer (Ausubel et al., 1992) . The gel was photographed with a Fotodyne 3-4400 ultraviolet transilluminator (Fotodyne Inc., New Berlin, WI) and Polaroid Positive-Negative 465 Instant Film (Polaroid Corp., Cambridge, MA).
Multiplex PCR for allele copy number determination
With samples #9651 and 9768 we performed a multiplex PCR with primers D6Mit50 and D6Mit29 along with the neutral D6Mit19 primer (in band C1, with no LOH) to determine the copy number of the C57/BL allele in the samples. The method here employed is an adaptation of a commonly used protocol (Schreiber and Dubeau, 1990 ) that has been successfully employed to determine gene ampli®cation by a number of other groups (Neubauer et al., 1992; An et al., 1995) . The reactions were performed in the same conditions as described above with the exception that two pairs of primers (D6Mit50 or D6Mit29 together with D6Mit19) were used for ampli®cation. The copy number determination was performed by densitometric evaluation of the C57/BL band in both primers (D6Mit50 or D6Mit29 and control). Since the samples employed were trisomic for the control primer (D6Mit19) with two alleles of C57/BL (measured by densitometry against the DBA/2 allele), a ratio between subject and control primers of more than 1.5 indicated three copies of the C57/BL allele in the subject primer.
Allelic-loss determination
The signal intensities of fragments were determined by densitometry or by visual examination by two reviewers.
We considered a sample to have LOH if an entire band was absent or if one band's intensity was less than 30% of the normal band's intensity . Although PCR ampli®cation cannot be considered quantitative, we optimized the PCR conditions so that equal amounts of template produced equal amounts of ampli®ed product. We used 27 ampli®cation cycles, which we demonstrated to be in the linear part of the ampli®cation process, i.e., before product saturation (data not shown). We also conducted a series of titrations using dierent proportions of homozygous and heterozygous templates to assess the in¯uence of stromal-tissue contamination of our ampli®cation reactions. We determined that we could detect as little as 30% contamination by heterozygotes template in the homozygous DNA (data not shown). Thus, our limit of 30% intensity for LOH is very conservative.
Statistical analysis
The normality of the percentage LOH distributions was tested by using Kolmogorov ± Smirnov continuous cumulative distribution test (Zar, 1991) .
